Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of mocravimod maintenance after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
ISRCTN12632431Phase 3Recruiting
- Sponsor
- Priothera
- Start
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mocravimod in acute myeloid leukemia (AML) (3 arms), sponsored by Priothera. Primary endpoint: Relapse-free survival. Started Jun 2022; status: recruiting.
02
Drugs
mocravimod
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN12632431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12632431.